A Phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 3, 2006, Pages 725-729

  Jin, Jing ^b   Li, Ye Xiong ^a   Liu, Yue Ping ^b   Wang, Wei Hu ^b   Song, Yong Wen ^b   Li, Tao ^b   Li, Ning ^b   Yu, Zi Hao ^b   Liu, Xin Fan ^b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b NONE

Author keywords

Adjuvant treatment; Capecitabine; Concurrent chemoradiotherapy; Rectal cancer

Indexed keywords

CHEMOTHERAPY; DRUG DOSAGE; TOXICITY; TUMORS;

ADJUVANT TREATMENT; CAPECITABINE; CONCURRENT CHEMORADIOTHERAPY; RECTAL CANCER;

RADIOTHERAPY;

CAPECITABINE; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RECTUM CANCER; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIARRHEA; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS;

EID: 31844452408     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.08.017     Document Type: Article

References (21)

1. Cancer Prevention and Control Office, Health Ministry Death survey for malignant tumor in China, 1975-1978 1979 Renmin Weisheng Publishing House Beijing
2. Gastrointestinal Tumor Study Group Prolongation of the disease-free interval in surgically treated rectal carcinoma N Engl J Med 312 1985 1465 1472
3. J.E. Krook, C.G. Moertel, L.L. Gunderson Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 1991 709 715
4. B. Fisher, N. Wolmark, H. Rocketter Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer Results from NSABP protocol R-01 J Natl Cancer Inst 80 1988 21 29
5. M.J. O'Connell, J.A. Martenson, H.S. Wieand Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery N Engl J Med 331 1994 502 507
6. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
7. J. Schüller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
8. G. Liu, E. Franssen, M.I. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
9. M. Borner, P. Schsffski, R. de Wit A randomized crossover trial comparing oral UFT (uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patients preference and pharmacokinetics in advanced colorectal cancer [Abstract] J Clin Oncol 19 2000 741a
10. S.A. Payne A study of quality of life in cancer patients receiving palliative chemotherapy Soc Sci Med 35 1992 1505 1509
11. N. Sawada, T. Ishikawa, F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
12. J. Dunst, T. Reese, S. Sutter Capecitabine combined with simultaneous radiotherapy in rectal cancer A phase I study J Clin Oncol 20 2002 3983 3991
13. J. Souglakos, N. Androulakis, S. Kakolyris Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operative rectal cancer Int J Radiat Oncol Biol Phys 56 2003 1284 1287
14. S. Ngan, M. Michael, J. Mackay A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially respectable rectal cancer Br J Cancer 91 2004 1019 1024
15. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed on July 15, 2005.
16. P.M. Hoff, R. Ansari, G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer Results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
17. E.V. Cutsem, C. Twelves, J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer Results of a large Phase III study J Clin Oncol 19 2001 4097 4106
18. E.V. Cutsem, P.M. Hoff, P. Harper Oral capecitabine vs intravenous 5-fluorouracil and leucovorin Integrated efficacy data and novel analyses from two large, randomized, phase III trials Br J Cancer 90 2004 1190 1197
19. C. Twelves, A. Wong, M.P. Nowacki Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 2005 2696 2704
20. J.S. Kim, J.S. Kim, M.J. Cho Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 54 2002 403 408
21. R. Sauer, H. Becker, W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740